The consistent application of a standardized pre-analytical method and ELISA for measuring sPD-1 and sPD-L1 levels across various tumor types in relatively large cohorts has provided valuable insights into the clinical utility of these soluble markers. The gene discussed is HOXD13; the disease is neoplasm.